Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A vaccine for heroin addiction?

Kelly PN.

Science. 2017 Jun 30;356(6345):1347-1348. doi: 10.1126/science.356.6345.1347-f. No abstract available.

PMID:
28663492
2.

Vaginal microbiome influences HIV acquisition.

Kelly PN.

Science. 2017 Jun 2;356(6341):918-919. doi: 10.1126/science.356.6341.918-g. No abstract available.

PMID:
28572367
3.

The NET effect of viral-triggered asthma.

Kelly PN.

Science. 2017 May 26;356(6340):817-818. doi: 10.1126/science.356.6340.817-d. No abstract available.

PMID:
28546202
4.

Targeting senescence to combat osteoarthritis.

Kelly PN.

Science. 2017 May 12;356(6338):595-596. doi: 10.1126/science.356.6338.595-b. No abstract available.

PMID:
28495739
5.

A way to switch off IBD.

Kelly PN.

Science. 2017 May 5;356(6337):497. doi: 10.1126/science.356.6337.497-d. Epub 2017 May 4. No abstract available.

PMID:
28473562
6.

Targeting nonviral antigens in viral-driven cancer.

Kelly PN.

Science. 2017 Apr 14;356(6334):149. doi: 10.1126/science.356.6334.149-a. Epub 2017 Apr 13. No abstract available.

PMID:
28408569
7.

Immune sensor maintains gut microbiome.

Kelly PN.

Science. 2017 Apr 7;356(6333):38. doi: 10.1126/science.356.6333.38-b. No abstract available.

PMID:
28385998
8.

CD28 is a critical target for PD-1 blockade.

Kelly PN.

Science. 2017 Mar 31;355(6332):1386. doi: 10.1126/science.355.6332.1386-b. No abstract available.

PMID:
28360298
9.

Notch1 promotes cancer spread.

Kelly PN.

Science. 2017 Mar 24;355(6331):1278-1279. doi: 10.1126/science.355.6331.1278-f. No abstract available.

PMID:
28336661
10.

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer M, Chaperot L, Plumas J, Jaffe ES, Thomas CJ, Reizis B, Staudt LM.

Cancer Cell. 2016 Nov 14;30(5):764-778. doi: 10.1016/j.ccell.2016.10.002.

11.

Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.

Grabow S, Kelly GL, Delbridge AR, Kelly PN, Bouillet P, Adams JM, Strasser A.

Cell Death Dis. 2016 Mar 10;7:e2132. doi: 10.1038/cddis.2016.43.

12.

Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Kelly PN, Romero DL, Yang Y, Shaffer AL 3rd, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R, Staudt LM.

J Exp Med. 2015 Dec 14;212(13):2189-201. doi: 10.1084/jem.20151074. Epub 2015 Nov 30.

13.

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.

14.

Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice.

Kelly PN, Grabow S, Delbridge AR, Adams JM, Strasser A.

Cell Death Differ. 2013 Jan;20(1):57-63. doi: 10.1038/cdd.2012.92. Epub 2012 Jul 20.

15.

Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.

Kelly PN, Grabow S, Delbridge AR, Strasser A, Adams JM.

Blood. 2011 Dec 8;118(24):6380-6. doi: 10.1182/blood-2011-07-367672. Epub 2011 Oct 12.

16.

Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.

Grabow S, Waring P, Happo L, Cook M, Mason KD, Kelly PN, Strasser A.

Cell Death Differ. 2012 Apr;19(4):623-32. doi: 10.1038/cdd.2011.133. Epub 2011 Oct 14.

17.

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy.

Kelly PN, Strasser A.

Cell Death Differ. 2011 Sep;18(9):1414-24. doi: 10.1038/cdd.2011.17. Epub 2011 Mar 18. Review.

18.

Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development.

Kelly PN, White MJ, Goschnick MW, Fairfax KA, Tarlinton DM, Kinkel SA, Bouillet P, Adams JM, Kile BT, Strasser A.

Cell Death Differ. 2010 Oct;17(10):1655-64. doi: 10.1038/cdd.2010.43. Epub 2010 Apr 30.

19.

Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation.

Jabbour AM, Daunt CP, Green BD, Vogel S, Gordon L, Lee RS, Silke N, Pearson RB, Vandenberg CJ, Kelly PN, Nutt SL, Strasser A, Borner C, Ekert PG.

Blood. 2010 Jan 14;115(2):344-52. doi: 10.1182/blood-2009-07-230730. Epub 2009 Nov 17.

20.

MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation.

O'Reilly LA, Kruse EA, Puthalakath H, Kelly PN, Kaufmann T, Huang DC, Strasser A.

J Immunol. 2009 Jul 1;183(1):261-9. doi: 10.4049/jimmunol.0803853.

21.

Role of "cancer stem cells" and cell survival in tumor development and maintenance.

Adams JM, Kelly PN, Dakic A, Carotta S, Nutt SL, Strasser A.

Cold Spring Harb Symp Quant Biol. 2008;73:451-9. doi: 10.1101/sqb.2008.73.004. Epub 2008 Nov 6. Review.

PMID:
19022754
22.

Tumor growth need not be driven by rare cancer stem cells.

Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A.

Science. 2007 Jul 20;317(5836):337.

23.

ER stress triggers apoptosis by activating BH3-only protein Bim.

Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, Gotoh T, Akira S, Bouillet P, Strasser A.

Cell. 2007 Jun 29;129(7):1337-49.

24.

Programmed anuclear cell death delimits platelet life span.

Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC, Kile BT.

Cell. 2007 Mar 23;128(6):1173-86.

25.

Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.

Kelly PN, Puthalakath H, Adams JM, Strasser A.

Blood. 2007 Jun 1;109(11):4907-13. Epub 2007 Feb 22.

26.

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. Epub 2006 Sep 22. Erratum in: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16614.

27.

Subversion of the Bcl-2 life/death switch in cancer development and therapy.

Adams JM, Huang DC, Strasser A, Willis S, Chen L, Wei A, van Delft M, Fletcher JI, Puthalakath H, Kuroda J, Michalak EM, Kelly PN, Bouillet P, Villunger A, O'Reilly L, Bath ML, Smith DP, Egle A, Harris AW, Hinds M, Colman P, Cory S.

Cold Spring Harb Symp Quant Biol. 2005;70:469-77.

PMID:
16869785
28.

Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim, and PI3 kinase, but depends in part on Puma.

Ekert PG, Jabbour AM, Manoharan A, Heraud JE, Yu J, Pakusch M, Michalak EM, Kelly PN, Callus B, Kiefer T, Verhagen A, Silke J, Strasser A, Borner C, Vaux DL.

Blood. 2006 Sep 1;108(5):1461-8. Epub 2006 May 16. Erratum in: Blood. 2017 Oct 5;130(14 ):1684.

29.

BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo.

Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, Adams JM, Strasser A, Villunger A.

Blood. 2005 Dec 15;106(13):4131-8. Epub 2005 Aug 23.

30.

Intermolecular interactions in N-(ferrocenylmethyl)anthracene-9-carboxamide.

Gallagher JF, Kelly PN, Kenny PT, Lough AJ.

Acta Crystallogr C. 2003 Dec;59(Pt 12):m552-4. Epub 2003 Nov 30.

PMID:
14671357

Supplemental Content

Loading ...
Support Center